MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from initial
public offering, net of...
$93,465K
Proceeds from issuance of
series c convertible...
$11,919K
Proceeds from exercises
of stock options
$205K
Net cash provided by
financing activities
$100,128K
Canceled cashflow
$5,461K
Increase in cash, cash
equivalents, and restricted...
$45,668K
Canceled cashflow
$54,460K
Payments for deferred
initial public offering...
$5,411K
Payment of issuance
costs related to term...
$50K
Accrued compensation
$2,490K
Accounts payable
$2,323K
Stock-based compensation
$1,927K
Provision for excess and
obsolete inventory
$1,839K
Accrued liabilities
$627K
Non-cash lease expense
$536K
Provision for credit
losses
$414K
Loss on
remeasurement of warrant...
$328K
Depreciation and
amortization
$281K
Non-cash interest
$206K
Other non-cash items
-$17K
Net cash used in
operating activities
-$28,977K
Net cash used in
investing activities
-$25,483K
Canceled cashflow
$10,988K
Net loss
-$29,634K
Purchase of short-term
investments
$24,000K
Capitalized software costs
$715K
Purchase of property and
equipment
$642K
Payment of initial
direct costs related to...
$126K
Accounts receivable, net
$5,010K
Inventory
$2,689K
Prepaid expenses and
other assets
$2,342K
Lease liabilities
-$290K
Back
Back
Cash Flow
source: myfinsight.com
CARLSMED, INC. (CARL)
CARLSMED, INC. (CARL)